Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Bio-Techne (TECH) over the last 17 years, with Q4 2025 value amounting to -$941000.0.

  • Bio-Techne's Change in Receivables fell 25104.33% to -$941000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$36.5 million, marking a year-over-year decrease of 28330.32%. This contributed to the annual value of -$34.1 million for FY2025, which is 26623.0% down from last year.
  • Latest data reveals that Bio-Techne reported Change in Receivables of -$941000.0 as of Q4 2025, which was down 25104.33% from -$22.4 million recorded in Q3 2025.
  • Over the past 5 years, Bio-Techne's Change in Receivables peaked at $51.6 million during Q1 2022, and registered a low of -$28.9 million during Q2 2025.
  • Moreover, its 5-year median value for Change in Receivables was $357500.0 (2023), whereas its average is $2.7 million.
  • In the last 5 years, Bio-Techne's Change in Receivables tumbled by 57662.91% in 2022 and then soared by 1938043.48% in 2024.
  • Quarter analysis of 5 years shows Bio-Techne's Change in Receivables stood at $5.7 million in 2021, then grew by 3.5% to $5.9 million in 2022, then tumbled by 180.1% to -$4.7 million in 2023, then surged by 113.16% to $623000.0 in 2024, then crashed by 251.04% to -$941000.0 in 2025.
  • Its last three reported values are -$941000.0 in Q4 2025, -$22.4 million for Q3 2025, and -$28.9 million during Q2 2025.